Michigan State University is dedicated to advancing cancer treatment through clinical trials across eight focus areas. The chart below lists all the faculty members actively working in these specific areas, showcasing their contributions to cancer research and clinical trials at MSU.
ACUTE MYELOID LEUKEMIA
CELGENE CONNECT MDS/AML/ICUS REGISTRY: An observational study of patients with newly diagnosed (within 2 months) MDS or AML. Patients are excluded if they have received treatment with active agents for MDS or AML prior to ICF date. Supportive care treatments are allowed
(Borys Hrinczenko, MD)
BENIGN HEMATOLOGY
ALEXION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) REGISTRY: A multi-center, multi-national, observational registry with enrollment of patients who diagnosed with PNH including patients previously treated with Soliris and withdrawn from treatment
(Borys Hrinczenko, MD)
BREAST CANCER
ALLIANCE A011401: Randomized Phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer. For Stage II or Stage III, HER2 negative, and ER/PR positive or negative breast cancer (BWEL Trial)
(Jatin Rana, MD)
BIG TEN BTCRC-BRE16-042: A Phase II study of pembrolizumab plus fulvestrant in hormone receptor positive, HER-2 negative advance/metastatic breast cancer patients
(Jatin Rana, MD)
NSABP B-59: A randomized, double-blind, Phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple-negative breast cancer followed by adjuvant continuation of atezolizumab or placebo
(Jatin Rana, MD)
SWOG S1418 (NRG BR006): A randomized, Phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with > 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapy
(Jatin Rana, MD)
GASTRIC CANCER
BIG TEN BTCRC-GI15-015: A Phase II study of FOLFOX combined with nab-paclitaxel (FOLFOX-A) in the treatment of metastatic or advanced unresectable gastric, gastro-esophageal junction adenocarcinoma
(Jatin Rana, MD)
LUNG CANCER
ALLIANCE A221504: A randomized, double-blind, placebo-controlled pilot study of an oral, selective peripheral opioid receptor antagonist in advanced non-small cell lung cancer (Adenocarcinoma) Stage IIIB or Stage IV
(Borys Hrinczenko, MD)
BIG TEN BTCRC-LUN16-081: A Phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable Stage IIIA/IIIB non-small cell lung cancer
(Borys Hrinczenko, MD)
MULTIPLE MYELOMA
GLAXOSMITHKLINE 207497: A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants with Relapsed / Refractory Multiple Myeloma – (DREAMM 6)
MYELODYSPLASTIC SYNDROME (MDS)
Myelodysplastic Syndrome (MDS) or Myeloproliferative Overlap Disorder
CELGENE CONNECT MDS/AML/ICUS REGISTRY: An observational study of patients with newly diagnosed (within 2 months) MDS or AML. Patients are excluded if they have received treatment with active agents for MDS or AML prior to ICF date. Supportive care treatments are allowed
(Borys Hrinczenko, MD)
Myelodysplastic Syndrome (MDS) including sub-type Chronic Myelomonocytic Leukemia (CMML)
ECOG NHLBI MDS: The National Myelodysplastic Syndromes (MDS) Study. A multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined significance (ICUS)
(Jatin Rana, MD)
PROSTATE CANCER
NRG-GU006:
A phase II, double-blinded, placebo-controlled randomized trial of salvage radiotherapy with or without enhanced anti-androgen therapy with apalutamide in recurrent prostate cancer
(Jatin Rana, MD)
For information about clinical trials at other institutions and hospital systems, please visit the national database.